Vancomycin is a glycopeptide antibiotic in clinical use as the primary treatment for methicillin-resistant Staphylococcus aureus (MRSA) and the only oral antibiotic reliably effective against Clostridioides difficile colitis. It is administered intravenously for systemic infections and orally for C. difficile. It is a reserve antibiotic used when other agents have failed or resistant organisms are confirmed.

Drug Class: Glycopeptide Antibiotic

Vancomycin belongs to the glycopeptide class that is structurally distinct from penicillins and cephalosporins and lacks a beta-lactam ring. This difference is clinically significant: vancomycin remains effective against bacteria resistant to beta-lactams. Other glycopeptides in clinical use include teicoplanin, dalbavancin, oritavancin, and telavancin.

Why Vancomycin Is Reserved for Serious Infections

Three factors cause vancomycin's reserve status: nephrotoxicity and ototoxicity require close monitoring; resistance is fatal with VRE and VRSA leaving extremely limited treatment options; and vancomycin is less potent against many organisms other antibiotics cover adequately so unnecessary use exposes the patient to toxicity without therapeutic benefit.

In Indian hospitals, vancomycin prescribing is governed by antimicrobial stewardship programmes requiring microbiological confirmation or strong clinical justification.

Conditions Vancomycin Is Used to Treat

Doctors prescribe vancomycin for:

• MRSA: Vancomycin is the cornerstone of treatment for MRSA bacteraemia, pneumonia, endocarditis, osteomyelitis, meningitis (though CNS penetration is limited) and MRSA skin and soft tissue infections requiring systemic IV treatment.

• Clostridioides difficile colitis: Oral vancomycin is not absorbed from the gut and reaches high colonic concentrations. Current guidelines support it as first-line for moderate-to-severe C. difficile colitis, replacing metronidazole. For severe fulminant C. difficile with ileus, vancomycin enemas may be added.

• Other Gram-positive infections: Coagulase-negative staphylococci (device-related infections and hospital-acquired bacteraemia), ampicillin-resistant Enterococcus faecium and empirically for febrile neutropenia with broad-spectrum Gram-negative cover.

How Vancomycin Is Administered

Intravenous vancomycin is the standard route for systemic infections, typically dosed at 15 to 20 mg/kg every eight to 12 hours for normal renal function. Each gram must be infused over at least 60 minutes to prevent infusion-related reactions. Loading doses of 25 to 30 mg/kg are used in critically ill patients or those with suspected MRSA meningitis to achieve faster target concentrations.

Oral vancomycin achieves no systemic blood levels and it acts within the gut lumen. For Clostridioides difficile colitis, oral dosing is typically 125 mg four times daily for 10 days (non-severe disease) or 500 mg four times daily for severe disease. 

How Vancomycin Kills Bacteria

Vancomycin is bactericidal. It binds with high affinity to the D-Ala–D-Ala terminus of peptidoglycan precursors, physically blocking the enzymes that cross-link peptidoglycan chains thereby preventing cell wall synthesis and causing the bacterium to lyse under its own osmotic pressure. The mechanism differs fundamentally from beta-lactam antibiotics, which inhibit the same enzymes by binding to penicillin-binding proteins.

Vancomycin is active exclusively against Gram-positive bacteria. Gram-negative bacteria are intrinsically resistant because their outer membrane is impermeable to vancomycin's large molecular structure.

Side Effects: From Common to Rare and Serious

Nephrotoxicity is the most clinically significant dose-related adverse effect. Risk increases with high AUC exposures, prolonged courses, concurrent nephrotoxic agents and pre-existing renal impairment. AUC-guided dosing reduces nephrotoxicity risk while maintaining efficacy. Other side effects are:

• Stomach pain, nausea or diarrhoea

• Ototoxicity - hearing loss and vestibular toxicity at high plasma concentrations and with prolonged courses.

• IV site thrombophlebitis

• Leucopenia and thrombocytopenia with prolonged use

• Drug fever

• Red Man Syndrome.

Red Man Syndrome - What Is It and Why Does It Happen?

Red Man Syndrome is not an allergic reaction but it is a rate-dependent infusion reaction caused by non-immunological histamine release when vancomycin is infused too quickly. The presentation is flushing, erythema and pruritus of the face, neck, and upper torso. Hypotension and rarely chest pain or muscle spasms can accompany the flushing.

The mechanism is not IgE-mediated and requires no prior sensitisation. Management: stop or slow the infusion, administer an antihistamine and restart at a slower rate. Premedication prevents recurrence. Each gram should be infused over at least 60 minutes and ideally over 90 minutes for doses above 1g.

Monitoring Required During Vancomycin Treatment

Therapeutic drug monitoring (TDM) is mandatory for vancomycin. The 2020 ASHP/IDSA/SIDP consensus guidelines recommend AUC monitoring with a target AUC/MIC ratio of 400 to 600 (mg·h/L) for MRSA infections. Bayesian software-assisted dosing is now recommended at centres with the capability.

Renal function must be monitored at least every 48 to 72 hours including serum creatinine, eGFR and urine output. If nephrotoxicity develops, vancomycin must be adjusted or an alternative considered. Audiological monitoring is needed for prolonged courses or concurrent ototoxic drugs. Complete blood count monitoring is appropriate for courses exceeding two weeks.

Drug Interactions to Be Aware Of

Key interactions are:

• Acyclovir

• Aminoglycosides like gentamicin, amikacin & tobramycin

• Anesthetic agents

• Live vaccines

• Loop diuretics like furosemide

• Metformin

• NSAIDs like ibuprofen, diclofenac, ketorolac

• Piperacillin-tazobactam 

• Warfarin.

Vancomycin Resistance - A Growing Concern

Vancomycin resistance occurs through modification of the D-Ala–D-Ala terminus that significantly reduces vancomycin binding affinity. One of the most important resistant bacteria is Vancomycin-resistant Enterococcus (VRE) predominantly Enterococcus faecium, which is a common cause of hospital-acquired infections worldwide. 

Vancomycin-resistant Staphylococcus aureus (VRSA) is rare but represents a catastrophic scenario with limited standard treatment options. Vancomycin-intermediate S. aureus (VISA) is more common and equally concerning, as standard doses may not achieve therapeutic concentrations. Reports from the Indian Council of Medical Research (ICMR) show that vancomycin resistance varies across hospitals in India, highlighting the importance of responsible antibiotic use and strong infection control practices.

FAQs

1. What is vancomycin used for?

   Primarily for serious MRSA infections including bacteraemia, pneumonia, endocarditis and others. Orally, it is first-line for moderate-to-severe Clostridioides difficile colitis. Also used for coagulase-negative staphylococcal infections, ampicillin-resistant Enterococcus and empirical febrile neutropenia.

2. Why is vancomycin considered a powerful antibiotic?

   Vancomycin is effective against gram-positive bacteria resistant to beta-lactam antibiotics through a completely different mechanism - narrow spectrum but strategically critical, covering organisms that leave few other treatment options.

3. What is Red Man Syndrome caused by vancomycin?

   Red Man Syndrome is an infusion-rate-dependent reaction, not an allergy. It occurs when vancomycin is infused too quickly, triggeringnon-immunological histamine release from mast cells, producing flushing, erythema and itching of the face, neck and upper torso. It is treated by slowing the infusion and giving an antihistamine and prevented by infusing over at least 60 minutes per gram.

4. Can vancomycin damage the kidneys or ears?

   Yes both are recognised adverse effects. Nephrotoxicity is the most clinically significant particularly with high AUC exposures, prolonged courses and concurrent nephrotoxic agents. Ototoxicity occurs at high concentrations especially with loop diuretics. Both are managed through therapeutic drug monitoring and renal function surveillance.

5. Is vancomycin used for MRSA infections?

   Yes vancomycin is the cornerstone of treatment for systemic MRSA infections: bacteraemia, endocarditis, pneumonia and osteomyelitis. For MRSA skin infections not requiring systemic treatment, oral alternatives such as trimethoprim-sulfamethoxazole, linezolid or doxycycline may be used.

6. Why do doctors monitor blood levels during vancomycin treatment?

   To balance efficacy and toxicity monitoring is essential as too low means inadequate treatment; too high increases nephrotoxicity and ototoxicity risk. Current guidelines recommend AUC-based monitoring rather than simple trough levels. 

7. Can vancomycin be taken orally as a tablet?

   Vancomycin oral therapy is used for Clostridioides difficile colitis, where its action in the gut lumen is therapeutic. In India, the intravenous preparation is diluted and given orally or via nasogastric tube; a dedicated oral formulation is not widely available.

8. How long does vancomycin treatment usually last?

   Duration is guided by clinical response and microbiological clearance:

   • MRSA bacteraemia: two to six weeks. 

   • MRSA endocarditis: six weeks. 

   • Clostridioides difficile colitis: 10 days. 

   • MRSA pneumonia: seven to 14 days. Osteomyelitis: four to six weeks.

9. What happens if vancomycin is infused too quickly?

   Red Man Syndrome - flushing, erythema and itching of the face, neck, and upper torso sometimes with hypotension and chest pain. Not dangerous if recognised and managed promptly. Vancomycin must be infused over at least 60 minutes per gram and over 90 minutes for doses above 1g.

10. Is vancomycin safe for use in children and newborns?

    Vancomycin is used in paediatric and neonatal practice with weight- and age-based dosing. In neonates, drug clearance is slower due to immature renal function so dosing intervals are extended accordingly. Therapeutic drug monitoring is mandatory.

References

1. Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2020;77(11):835–64. https://doi.org/10.1093/ajhp/zxaa036

2. Blumenthal KG, Patil SU, Long AA. The importance of vancomycin in drug rash with eosinophilia and systemic symptoms (DRESS) and the role of the lymphocyte transformation test. J Allergy Clin Immunol Pract. 2012;109(6):1525–30. https://doi.org/10.1016/j.jaci.2012.02.028

3. Parente DM, Cunha CB, Mylonakis E, Timbrook TT. The clinical utility of methicillin-resistant Staphylococcus aureus (MRSA) nasal screening to rule out MRSA pneumonia. Clin Infect Dis. 2018;67(1):1–7. https://doi.org/10.1093/cid/ciy024

4. ACOG Practice Bulletin. Prevention of Group B Streptococcal Early-Onset Disease in Newborns: ACOG Practice Bulletin, Number 797. Obstet Gynecol. 2020;135(2):e51–e72. https://doi.org/10.1097/AOG.0000000000003668

5. Blumenthal KG, Youngster I, Rabideau DJ, et al. Peripheral blood eosinophilia and hypersensitivity reactions among patients receiving outpatient parenteral antibiotics. J Allergy Clin Immunol. 2015;136(5):1288–94. https://doi.org/10.1016/j.jaci.2015.04.023